RecruitingNCT07250100

The Role of Microbiota in Pancreatic Cancer and Precursor Lesions

Sponsor

Herlev Hospital

Enrollment

300 participants

Start Date

Nov 1, 2025

Study Type

OBSERVATIONAL

Conditions

Pancreatic Cancer Microbiome

Summary

This is a prospective observational study aiming to investigate the microbiome in patients suspected of having pancreatic cancer. The purpose is to enhance diagnostic accuracy by developing screening protocols for high-risk individuals, identifying specific microbial biomarkers, and improving prognostic criteria to optimize treatment response. Participants will be asked to complete a questionnaire, provide oral and fecal swabs, and-if clinically indicated-1-2 pancreatic biopsies will be collected.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational study collects samples from patients undergoing procedures for a suspected pancreatic lesion (solid or cystic) to study the role of gut and pancreatic microbiota (bacteria and other microorganisms) in the development of pancreatic cancer. No experimental treatment is involved. **You may be eligible if...** - You are 18 or older - You have a suspected lesion in the pancreas and are already scheduled for a diagnostic or therapeutic endoscopic procedure - You are willing to provide written consent **You may NOT be eligible if...** - You have a condition that makes endoscopic or surgical procedures unsafe, such as an uncorrected bleeding disorder Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERobservational study

Aprox. 300 patients suspected of pancreatic cancer. Of those, minimum of 50 patients with histologically confirmed PDAC in each of the stages I-II, III and IV, as some of the participants will be diagnosed with a non-malignant disease and will constitute the control group.

Locations(1)

Herlev og Gentofte Hospital

Herlev, Capital Region, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07250100

Related Trials

Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety)

NCT056577432 locations

Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer

NCT0669845815 locations

Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer

NCT060269431 location

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

NCT0500540346 locations

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

NCT028307241 location